The Heterozygous Familial Hypercholesterolemia HEFH Management Market is witnessing a significant transformation, driven by an increasing prevalence of this genetic condition and a growing awareness of its implications. As we approach 2035, the market is expected to grow from $8.16 billion in 2024 to $15.75 billion, marking a robust CAGR of 6.16%. This growth is indicative of a burgeoning...